Dean Michael Cestari, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Optic Neuropathy, Ischemic | 11 | 2024 | 86 | 2.880 |
Why?
|
| Optic Nerve Diseases | 11 | 2020 | 342 | 2.750 |
Why?
|
| Oculomotor Muscles | 7 | 2023 | 407 | 2.220 |
Why?
|
| Optic Neuritis | 8 | 2019 | 174 | 2.120 |
Why?
|
| Optic Disk | 10 | 2018 | 421 | 2.000 |
Why?
|
| Eye Diseases | 6 | 2019 | 651 | 1.820 |
Why?
|
| Optic Atrophy, Hereditary, Leber | 5 | 2021 | 50 | 1.410 |
Why?
|
| Esotropia | 3 | 2019 | 99 | 1.360 |
Why?
|
| Optic Disk Drusen | 2 | 2021 | 38 | 1.330 |
Why?
|
| Vision Disorders | 11 | 2020 | 1084 | 1.140 |
Why?
|
| Fluorescein Angiography | 9 | 2021 | 1044 | 1.130 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2019 | 353 | 1.110 |
Why?
|
| Optic Nerve | 7 | 2022 | 567 | 1.070 |
Why?
|
| Tomography, Optical Coherence | 11 | 2021 | 2877 | 0.980 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 3 | 2018 | 250 | 0.910 |
Why?
|
| Graves Ophthalmopathy | 4 | 2018 | 133 | 0.910 |
Why?
|
| Retinal Ganglion Cells | 5 | 2017 | 806 | 0.870 |
Why?
|
| Intracranial Hypertension | 3 | 2021 | 193 | 0.850 |
Why?
|
| Giant Cell Arteritis | 4 | 2017 | 297 | 0.850 |
Why?
|
| Abducens Nerve Diseases | 2 | 2015 | 44 | 0.810 |
Why?
|
| Strabismus | 2 | 2018 | 317 | 0.780 |
Why?
|
| Ophthalmology | 4 | 2020 | 549 | 0.760 |
Why?
|
| Neuromyelitis Optica | 3 | 2019 | 259 | 0.760 |
Why?
|
| Nystagmus, Pathologic | 2 | 2014 | 105 | 0.760 |
Why?
|
| Macula Lutea | 2 | 2021 | 169 | 0.730 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2020 | 45 | 0.720 |
Why?
|
| Visual Fields | 8 | 2018 | 1054 | 0.710 |
Why?
|
| Nervous System Diseases | 3 | 2018 | 1647 | 0.690 |
Why?
|
| Neurofibromatosis 1 | 2 | 2019 | 560 | 0.680 |
Why?
|
| Eye Infections | 1 | 2019 | 62 | 0.660 |
Why?
|
| Cranial Nerve Diseases | 1 | 2020 | 112 | 0.660 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2019 | 53 | 0.650 |
Why?
|
| Scotoma | 3 | 2017 | 130 | 0.650 |
Why?
|
| Vascular Neoplasms | 1 | 2020 | 167 | 0.630 |
Why?
|
| Mitochondrial Diseases | 2 | 2016 | 340 | 0.620 |
Why?
|
| DNA, Mitochondrial | 4 | 2021 | 856 | 0.620 |
Why?
|
| Vision, Low | 3 | 2009 | 163 | 0.610 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2019 | 104 | 0.610 |
Why?
|
| Retinal Vessels | 3 | 2018 | 836 | 0.590 |
Why?
|
| Eye Neoplasms | 1 | 2019 | 306 | 0.590 |
Why?
|
| Arteritis | 2 | 2016 | 159 | 0.580 |
Why?
|
| Vision, Binocular | 1 | 2019 | 225 | 0.580 |
Why?
|
| Meningioma | 2 | 2020 | 1217 | 0.580 |
Why?
|
| Diplopia | 2 | 2023 | 215 | 0.570 |
Why?
|
| Pseudotumor Cerebri | 1 | 2018 | 108 | 0.570 |
Why?
|
| Visual Acuity | 8 | 2020 | 2642 | 0.550 |
Why?
|
| Optic Nerve Injuries | 1 | 2017 | 147 | 0.540 |
Why?
|
| Eye | 2 | 2023 | 710 | 0.530 |
Why?
|
| Autoantigens | 2 | 2018 | 877 | 0.520 |
Why?
|
| Eye Movements | 1 | 2019 | 508 | 0.520 |
Why?
|
| Blindness | 3 | 2016 | 582 | 0.520 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2019 | 2159 | 0.520 |
Why?
|
| Orbital Neoplasms | 1 | 2017 | 221 | 0.510 |
Why?
|
| Visual Field Tests | 7 | 2020 | 411 | 0.510 |
Why?
|
| Central Nervous System Diseases | 1 | 2020 | 520 | 0.500 |
Why?
|
| Hemangioma, Cavernous | 1 | 2015 | 107 | 0.490 |
Why?
|
| Temporal Arteries | 3 | 2011 | 148 | 0.480 |
Why?
|
| Injections, Intraocular | 1 | 2014 | 33 | 0.480 |
Why?
|
| Huntington Disease | 1 | 2021 | 1141 | 0.480 |
Why?
|
| Tacrolimus | 1 | 2018 | 733 | 0.470 |
Why?
|
| Horner Syndrome | 1 | 2014 | 36 | 0.470 |
Why?
|
| Retinal Artery Occlusion | 2 | 2016 | 77 | 0.460 |
Why?
|
| Sarcoidosis | 1 | 2020 | 520 | 0.460 |
Why?
|
| GTP Phosphohydrolases | 2 | 2017 | 517 | 0.460 |
Why?
|
| Autonomic Nerve Block | 1 | 2014 | 80 | 0.450 |
Why?
|
| Optic Atrophy, Autosomal Dominant | 1 | 2013 | 8 | 0.450 |
Why?
|
| Leiomyosarcoma | 1 | 2017 | 424 | 0.450 |
Why?
|
| Cataract Extraction | 1 | 2017 | 465 | 0.430 |
Why?
|
| Sensory Deprivation | 1 | 2013 | 106 | 0.430 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 2244 | 0.430 |
Why?
|
| Fundus Oculi | 4 | 2020 | 540 | 0.430 |
Why?
|
| Nerve Regeneration | 2 | 2022 | 790 | 0.430 |
Why?
|
| Tuberous Sclerosis | 1 | 2019 | 1030 | 0.380 |
Why?
|
| Evoked Potentials, Visual | 3 | 2021 | 415 | 0.380 |
Why?
|
| Axons | 3 | 2022 | 1673 | 0.380 |
Why?
|
| Retina | 3 | 2020 | 2635 | 0.380 |
Why?
|
| Amblyopia | 1 | 2013 | 150 | 0.380 |
Why?
|
| Interferon-alpha | 1 | 2015 | 918 | 0.370 |
Why?
|
| Retinal Vasculitis | 1 | 2011 | 46 | 0.370 |
Why?
|
| Point Mutation | 1 | 2016 | 1593 | 0.360 |
Why?
|
| Hypotension | 1 | 2016 | 879 | 0.350 |
Why?
|
| Whipple Disease | 1 | 2010 | 20 | 0.350 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 1402 | 0.350 |
Why?
|
| Glucocorticoids | 4 | 2018 | 2144 | 0.340 |
Why?
|
| Humans | 83 | 2024 | 758406 | 0.340 |
Why?
|
| Photochemotherapy | 1 | 2016 | 820 | 0.340 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 1292 | 0.340 |
Why?
|
| Ethambutol | 1 | 2008 | 59 | 0.320 |
Why?
|
| Waldenstrom Macroglobulinemia | 3 | 2016 | 1067 | 0.320 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 1439 | 0.320 |
Why?
|
| Hemianopsia | 1 | 2010 | 121 | 0.320 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2008 | 59 | 0.320 |
Why?
|
| Neuromuscular Agents | 1 | 2010 | 148 | 0.310 |
Why?
|
| Vaccines, Inactivated | 1 | 2009 | 179 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2020 | 36284 | 0.300 |
Why?
|
| Immunosuppressive Agents | 4 | 2020 | 4158 | 0.290 |
Why?
|
| Intracranial Pressure | 2 | 2021 | 325 | 0.290 |
Why?
|
| Parkinson Disease | 1 | 2021 | 2862 | 0.290 |
Why?
|
| Cataract | 1 | 2013 | 827 | 0.290 |
Why?
|
| Immunoglobulin G | 2 | 2018 | 4540 | 0.280 |
Why?
|
| Papilledema | 3 | 2018 | 130 | 0.280 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2010 | 229 | 0.280 |
Why?
|
| Eye Infections, Bacterial | 1 | 2010 | 239 | 0.280 |
Why?
|
| Arthralgia | 2 | 2011 | 461 | 0.270 |
Why?
|
| Solitary Nucleus | 2 | 1996 | 54 | 0.260 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 5484 | 0.250 |
Why?
|
| Diagnostic Imaging | 2 | 2018 | 3526 | 0.250 |
Why?
|
| Middle Aged | 29 | 2024 | 219568 | 0.250 |
Why?
|
| Circadian Rhythm | 1 | 2016 | 2567 | 0.240 |
Why?
|
| Leukocytosis | 3 | 2018 | 251 | 0.240 |
Why?
|
| Retinal Degeneration | 1 | 2008 | 412 | 0.230 |
Why?
|
| Aquaporin 4 | 2 | 2019 | 159 | 0.230 |
Why?
|
| Male | 41 | 2024 | 358747 | 0.220 |
Why?
|
| Brain | 6 | 2021 | 26947 | 0.220 |
Why?
|
| Blood Patch, Epidural | 1 | 2003 | 56 | 0.220 |
Why?
|
| Hemorrhage | 1 | 2015 | 3400 | 0.220 |
Why?
|
| Autoantibodies | 3 | 2019 | 2118 | 0.220 |
Why?
|
| Brain Diseases | 1 | 2012 | 1541 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 9160 | 0.210 |
Why?
|
| Glucagon-Like Peptides | 1 | 2024 | 153 | 0.210 |
Why?
|
| Antiviral Agents | 1 | 2015 | 3056 | 0.210 |
Why?
|
| Acetazolamide | 2 | 2018 | 96 | 0.210 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 18119 | 0.210 |
Why?
|
| Hearing Loss | 1 | 2010 | 780 | 0.200 |
Why?
|
| Stroke | 2 | 2020 | 9694 | 0.200 |
Why?
|
| Diagnosis, Differential | 7 | 2019 | 12951 | 0.190 |
Why?
|
| Influenza Vaccines | 1 | 2009 | 759 | 0.190 |
Why?
|
| Recurrence | 5 | 2020 | 8426 | 0.190 |
Why?
|
| Electroretinography | 2 | 2016 | 517 | 0.190 |
Why?
|
| Meningeal Neoplasms | 1 | 2010 | 1247 | 0.180 |
Why?
|
| Retinal Hemorrhage | 1 | 2021 | 95 | 0.180 |
Why?
|
| Sex Reassignment Procedures | 1 | 2021 | 70 | 0.180 |
Why?
|
| Spinal Puncture | 2 | 2018 | 281 | 0.180 |
Why?
|
| Myelin Sheath | 2 | 2022 | 652 | 0.180 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 8544 | 0.170 |
Why?
|
| Antitubercular Agents | 1 | 2008 | 1373 | 0.170 |
Why?
|
| Skull Base Neoplasms | 2 | 2015 | 269 | 0.170 |
Why?
|
| Mutation | 6 | 2021 | 29915 | 0.170 |
Why?
|
| Visual Pathways | 2 | 2016 | 534 | 0.170 |
Why?
|
| Eye Pain | 1 | 2019 | 46 | 0.160 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 4 | 2020 | 2782 | 0.160 |
Why?
|
| Glaucoma | 1 | 2008 | 1182 | 0.160 |
Why?
|
| Female | 28 | 2024 | 390323 | 0.160 |
Why?
|
| Immunomodulation | 2 | 2020 | 545 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 2638 | 0.160 |
Why?
|
| Brain Infarction | 2 | 2012 | 290 | 0.160 |
Why?
|
| Orbital Diseases | 1 | 2020 | 178 | 0.160 |
Why?
|
| Multiple Sclerosis | 4 | 2020 | 3204 | 0.160 |
Why?
|
| Oligodendroglia | 1 | 2022 | 536 | 0.150 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2018 | 91 | 0.150 |
Why?
|
| Amygdala | 2 | 1996 | 1350 | 0.150 |
Why?
|
| Ciliary Arteries | 1 | 2017 | 19 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2009 | 1516 | 0.150 |
Why?
|
| Orbital Implants | 1 | 2017 | 22 | 0.150 |
Why?
|
| Capillaries | 2 | 2017 | 744 | 0.150 |
Why?
|
| Coloboma | 1 | 2017 | 59 | 0.140 |
Why?
|
| Basal Ganglia Diseases | 1 | 2017 | 144 | 0.140 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2021 | 701 | 0.140 |
Why?
|
| Nerve Fibers | 2 | 2017 | 708 | 0.140 |
Why?
|
| Biopsy | 2 | 2020 | 6768 | 0.140 |
Why?
|
| Mycophenolic Acid | 1 | 2019 | 343 | 0.140 |
Why?
|
| Thailand | 1 | 2017 | 288 | 0.140 |
Why?
|
| Retinal Telangiectasis | 1 | 2016 | 25 | 0.140 |
Why?
|
| Synapses | 2 | 1996 | 1757 | 0.130 |
Why?
|
| Rats, Inbred BN | 1 | 2016 | 231 | 0.130 |
Why?
|
| Vision, Monocular | 1 | 2016 | 71 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 6313 | 0.130 |
Why?
|
| Orbit | 2 | 2017 | 446 | 0.130 |
Why?
|
| Myasthenia Gravis | 1 | 2018 | 212 | 0.130 |
Why?
|
| Aged | 16 | 2024 | 168218 | 0.130 |
Why?
|
| Efferent Pathways | 1 | 1996 | 165 | 0.130 |
Why?
|
| Photophobia | 1 | 2016 | 71 | 0.130 |
Why?
|
| Adult | 22 | 2021 | 219935 | 0.130 |
Why?
|
| Nerve Compression Syndromes | 1 | 2017 | 160 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 5246 | 0.120 |
Why?
|
| Cerebrospinal Fluid | 1 | 2018 | 544 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2017 | 15637 | 0.120 |
Why?
|
| Steroids | 1 | 2020 | 926 | 0.120 |
Why?
|
| Vision, Ocular | 1 | 2018 | 454 | 0.120 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 2016 | 180 | 0.120 |
Why?
|
| Optic Chiasm | 1 | 2014 | 91 | 0.120 |
Why?
|
| Blood Sedimentation | 1 | 2015 | 234 | 0.120 |
Why?
|
| Headache | 2 | 2018 | 1248 | 0.120 |
Why?
|
| Postoperative Period | 1 | 2019 | 1812 | 0.120 |
Why?
|
| Dystonia | 1 | 2017 | 366 | 0.120 |
Why?
|
| Intracranial Aneurysm | 1 | 2004 | 1276 | 0.110 |
Why?
|
| Endoscopy | 2 | 2017 | 1834 | 0.110 |
Why?
|
| Hormone Replacement Therapy | 1 | 2019 | 754 | 0.110 |
Why?
|
| Angiography | 1 | 2018 | 1599 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2013 | 310 | 0.100 |
Why?
|
| Decompression, Surgical | 1 | 2017 | 604 | 0.100 |
Why?
|
| Anesthesia, Local | 1 | 2014 | 276 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 2017 | 1034 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 20500 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2016 | 8143 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 3069 | 0.100 |
Why?
|
| Panuveitis | 1 | 2011 | 33 | 0.090 |
Why?
|
| General Practitioners | 1 | 2012 | 101 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 13245 | 0.090 |
Why?
|
| Retrospective Studies | 11 | 2024 | 80168 | 0.090 |
Why?
|
| Managed Care Programs | 1 | 2016 | 939 | 0.090 |
Why?
|
| Erythrocyte Transfusion | 1 | 2016 | 563 | 0.090 |
Why?
|
| Fractures, Bone | 1 | 2023 | 2040 | 0.090 |
Why?
|
| Sweet Syndrome | 1 | 2011 | 58 | 0.090 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 1996 | 1132 | 0.090 |
Why?
|
| Cauda Equina | 1 | 2010 | 45 | 0.090 |
Why?
|
| Electrophysiology | 1 | 2013 | 1263 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2015 | 1177 | 0.090 |
Why?
|
| Tropheryma | 1 | 2010 | 4 | 0.090 |
Why?
|
| Genetic Testing | 2 | 2017 | 3530 | 0.090 |
Why?
|
| Positron-Emission Tomography | 2 | 2017 | 6457 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2018 | 2693 | 0.090 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 39059 | 0.090 |
Why?
|
| Lymphocytes | 1 | 2018 | 2610 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 785 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2011 | 1870 | 0.090 |
Why?
|
| Thalamus | 1 | 2016 | 1040 | 0.090 |
Why?
|
| Prognosis | 4 | 2020 | 29557 | 0.080 |
Why?
|
| Sphenoid Bone | 1 | 2010 | 177 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2016 | 955 | 0.080 |
Why?
|
| Injections, Intramuscular | 1 | 2010 | 553 | 0.080 |
Why?
|
| Neural Pathways | 3 | 1996 | 3039 | 0.080 |
Why?
|
| Rats | 6 | 2016 | 23679 | 0.080 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2008 | 76 | 0.080 |
Why?
|
| Immunocompetence | 1 | 2008 | 138 | 0.080 |
Why?
|
| Enophthalmos | 1 | 2008 | 34 | 0.080 |
Why?
|
| Myelitis, Transverse | 1 | 2008 | 40 | 0.080 |
Why?
|
| Testosterone | 1 | 2019 | 2471 | 0.080 |
Why?
|
| Neurons | 3 | 2016 | 9416 | 0.080 |
Why?
|
| Genetic Linkage | 1 | 2013 | 2381 | 0.080 |
Why?
|
| Genes, Neurofibromatosis 1 | 1 | 2008 | 74 | 0.070 |
Why?
|
| Aged, 80 and over | 8 | 2017 | 58683 | 0.070 |
Why?
|
| Genome, Mitochondrial | 1 | 2008 | 66 | 0.070 |
Why?
|
| Anesthetics, Local | 1 | 2014 | 1000 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 1431 | 0.070 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2008 | 121 | 0.070 |
Why?
|
| Orbital Fractures | 1 | 2008 | 109 | 0.070 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2008 | 203 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 4901 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 2004 | 0.070 |
Why?
|
| Maxillary Sinus | 1 | 2008 | 180 | 0.070 |
Why?
|
| Young Adult | 6 | 2021 | 58808 | 0.070 |
Why?
|
| Neurofibromin 1 | 1 | 2008 | 190 | 0.070 |
Why?
|
| Viral Load | 1 | 2015 | 3321 | 0.070 |
Why?
|
| Paranasal Sinuses | 1 | 2008 | 265 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 2634 | 0.060 |
Why?
|
| Risk Factors | 5 | 2024 | 73809 | 0.060 |
Why?
|
| Craniotomy | 1 | 2010 | 741 | 0.060 |
Why?
|
| Mycoses | 1 | 2008 | 386 | 0.060 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 3024 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2018 | 3245 | 0.060 |
Why?
|
| Behcet Syndrome | 1 | 2006 | 86 | 0.060 |
Why?
|
| Electromyography | 1 | 2010 | 1388 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2015 | 1579 | 0.060 |
Why?
|
| Maxilla | 1 | 2008 | 491 | 0.060 |
Why?
|
| Seizures | 1 | 2017 | 2919 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 3339 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2020 | 4641 | 0.060 |
Why?
|
| Life Tables | 1 | 2004 | 365 | 0.060 |
Why?
|
| Microscopy, Electron | 3 | 1996 | 2557 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2017 | 41256 | 0.060 |
Why?
|
| Carcinoma | 1 | 2015 | 2330 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2019 | 64378 | 0.060 |
Why?
|
| Animals | 8 | 2017 | 167768 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3812 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 2016 | 1694 | 0.060 |
Why?
|
| Nasal Polyps | 1 | 2008 | 395 | 0.050 |
Why?
|
| Culture | 1 | 2007 | 624 | 0.050 |
Why?
|
| Head | 1 | 2009 | 921 | 0.050 |
Why?
|
| Pattern Recognition, Visual | 1 | 2008 | 810 | 0.050 |
Why?
|
| Presynaptic Terminals | 2 | 1995 | 301 | 0.050 |
Why?
|
| Intracranial Embolism | 1 | 2004 | 189 | 0.050 |
Why?
|
| Adolescent | 5 | 2021 | 87892 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2015 | 2332 | 0.050 |
Why?
|
| Limbic System | 2 | 1994 | 419 | 0.050 |
Why?
|
| Neurosurgical Procedures | 2 | 2010 | 2055 | 0.050 |
Why?
|
| Injections, Epidural | 1 | 2003 | 200 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 12440 | 0.050 |
Why?
|
| New York City | 1 | 2004 | 725 | 0.050 |
Why?
|
| Thrombophilia | 1 | 2004 | 304 | 0.050 |
Why?
|
| Systemic Vasculitis | 1 | 2020 | 36 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 12075 | 0.040 |
Why?
|
| Apoptosis | 1 | 2016 | 9468 | 0.040 |
Why?
|
| Retinal Diseases | 1 | 2006 | 702 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 1055 | 0.040 |
Why?
|
| Sinusitis | 1 | 2008 | 990 | 0.040 |
Why?
|
| Phosphorus Radioisotopes | 1 | 2018 | 100 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2010 | 3485 | 0.040 |
Why?
|
| United States | 2 | 2017 | 72136 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 1996 | 11070 | 0.040 |
Why?
|
| Aneurysm, Ruptured | 1 | 2004 | 459 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2008 | 2970 | 0.040 |
Why?
|
| Carbidopa | 1 | 2017 | 30 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2020 | 616 | 0.040 |
Why?
|
| Catecholamines | 2 | 1995 | 385 | 0.040 |
Why?
|
| Demyelinating Diseases | 1 | 2020 | 351 | 0.040 |
Why?
|
| Tegmentum Mesencephali | 2 | 1994 | 59 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 1788 | 0.040 |
Why?
|
| Levodopa | 1 | 2017 | 217 | 0.040 |
Why?
|
| Face | 1 | 2023 | 1017 | 0.030 |
Why?
|
| Biotin | 1 | 2017 | 253 | 0.030 |
Why?
|
| Thiamine | 1 | 2017 | 160 | 0.030 |
Why?
|
| Phytohemagglutinins | 1 | 1995 | 168 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2017 | 527 | 0.030 |
Why?
|
| Dendrites | 2 | 1995 | 474 | 0.030 |
Why?
|
| Incidence | 2 | 2024 | 21272 | 0.030 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2017 | 285 | 0.030 |
Why?
|
| Neurons, Efferent | 1 | 1995 | 81 | 0.030 |
Why?
|
| Neoplasms | 1 | 2004 | 22032 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 7378 | 0.030 |
Why?
|
| Microinjections | 1 | 1995 | 321 | 0.030 |
Why?
|
| Stilbamidines | 1 | 1994 | 43 | 0.030 |
Why?
|
| Macrophages | 1 | 2010 | 5737 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 11709 | 0.030 |
Why?
|
| Afferent Pathways | 1 | 1995 | 298 | 0.030 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1995 | 370 | 0.030 |
Why?
|
| Europe | 1 | 2021 | 3420 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2004 | 1407 | 0.030 |
Why?
|
| Microvessels | 1 | 2017 | 572 | 0.030 |
Why?
|
| Vincristine | 1 | 2016 | 1038 | 0.030 |
Why?
|
| Paraproteinemias | 1 | 2016 | 246 | 0.030 |
Why?
|
| Age of Onset | 1 | 2020 | 3298 | 0.030 |
Why?
|
| Serotonin | 2 | 1994 | 1040 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2020 | 42062 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2017 | 2020 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 1995 | 589 | 0.020 |
Why?
|
| Fourier Analysis | 1 | 2012 | 439 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2004 | 10112 | 0.020 |
Why?
|
| Retinal Detachment | 1 | 2016 | 427 | 0.020 |
Why?
|
| Age Factors | 1 | 2008 | 18358 | 0.020 |
Why?
|
| Disease Progression | 1 | 2008 | 13468 | 0.020 |
Why?
|
| Meningitis, Aseptic | 1 | 2011 | 59 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2018 | 1236 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 1994 | 663 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 1368 | 0.020 |
Why?
|
| Prevalence | 1 | 2007 | 15651 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2016 | 2218 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2016 | 1967 | 0.020 |
Why?
|
| Comorbidity | 1 | 2004 | 10495 | 0.020 |
Why?
|
| Radioisotopes | 1 | 2010 | 495 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 3754 | 0.020 |
Why?
|
| Embolism | 1 | 2012 | 401 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 4106 | 0.020 |
Why?
|
| Thrombocytosis | 1 | 2009 | 81 | 0.020 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 2008 | 8 | 0.020 |
Why?
|
| Ophthalmic Artery | 1 | 2009 | 58 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 2012 | 0.020 |
Why?
|
| Nasal Bone | 1 | 2008 | 57 | 0.020 |
Why?
|
| Hypertension | 2 | 2009 | 8499 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2017 | 2564 | 0.020 |
Why?
|
| Methotrexate | 1 | 2014 | 1719 | 0.020 |
Why?
|
| Smoking | 1 | 2004 | 9051 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2014 | 1927 | 0.020 |
Why?
|
| Dopamine | 1 | 1994 | 1599 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2018 | 2055 | 0.020 |
Why?
|
| Cyclopentolate | 1 | 2006 | 6 | 0.020 |
Why?
|
| Diabetic Retinopathy | 1 | 2016 | 1267 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 17768 | 0.020 |
Why?
|
| Exanthema | 1 | 2011 | 504 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 4711 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2014 | 1530 | 0.020 |
Why?
|
| Anemia | 1 | 2016 | 1504 | 0.020 |
Why?
|
| Mydriatics | 1 | 2006 | 67 | 0.020 |
Why?
|
| Genital Diseases, Male | 1 | 2006 | 83 | 0.020 |
Why?
|
| Gadolinium | 1 | 2010 | 959 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2006 | 96 | 0.020 |
Why?
|
| Prednisolone | 1 | 2006 | 326 | 0.020 |
Why?
|
| Ulcer | 1 | 2006 | 204 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8530 | 0.010 |
Why?
|
| Fever | 1 | 2011 | 1617 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 2210 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 8981 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2009 | 2640 | 0.010 |
Why?
|
| Proteins | 1 | 2017 | 6026 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2009 | 2253 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2011 | 1585 | 0.010 |
Why?
|
| Syndrome | 1 | 2008 | 3262 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 1793 | 0.010 |
Why?
|
| Radiography | 1 | 2012 | 6954 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 2 | 1994 | 1705 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 11336 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2017 | 7843 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 4342 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 2731 | 0.010 |
Why?
|
| Neutrophils | 1 | 2011 | 3765 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 6293 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 2476 | 0.010 |
Why?
|
| Gold Colloid | 1 | 1994 | 12 | 0.010 |
Why?
|
| Silver Staining | 1 | 1994 | 62 | 0.010 |
Why?
|
| Wheat Germ Agglutinins | 1 | 1994 | 47 | 0.010 |
Why?
|
| Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate | 1 | 1994 | 35 | 0.010 |
Why?
|
| Horseradish Peroxidase | 1 | 1994 | 166 | 0.010 |
Why?
|
| Fluorescence | 1 | 1994 | 749 | 0.010 |
Why?
|
| Child | 1 | 2020 | 79818 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1994 | 1897 | 0.000 |
Why?
|
| Time Factors | 1 | 2008 | 39872 | 0.000 |
Why?
|